Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRACK trial: low-dose rivaroxaban in advanced chronic kidney disease
2020-000334-17Phase 3Active
- Sponsor
- The George Institute for Global Health
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of rivaroxaban in cardiac morbidity and chronic kidney disease (CKD) (2 arms), sponsored by The George Institute for Global Health. Primary endpoint: Primary composite cardiovascular outcome. Started Dec 2022; status: active.
02
Drugs
rivaroxaban
03
Conditions
cardiac morbiditychronic kidney disease (CKD)
Beyond the preview
Go deeper on 2020-000334-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000334-17.